Bear market? These small caps buck the trend

Here are our top 3 investment ideas today. These settings look done! And don’t forget to vote in ours new poll on the bottom. Let us know what you think!

LMDX – Increase of over 150% pre-market after partnering with AstraZenica for England’s first heart and lung screening center

ACON – Up over 9% before after signing letter of intent with ATEC to advance commercialization of Nociscan

HARP – Up more than 13% before after announcement of 35% response in Phase 1/2 small cell lung cancer clinical trial

Would you agree? The market has been an oppressive tyrant for some time now – but Jeff Bishop and his loyal subscribers aren’t giving up. They have fought hand to hand since that terrible September! It looks exactly like this:

And the drop in minutes is Jeff’s next pick of the week 🎯at Bullseye Trades. Bullseye last week (bets vs NVDA) could earn you 300% – Was it If not…

LMDX – Up over 150% in pre-market after announcing partnership with AstraZenica for England’s first heart and lung screening center

LumiraDx (LMDX) operates as a point diagnosis company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers.

Late on Friday after hours, the company announced a partnership with AstraZeneca and Everton in the Community (the official charity of Everton Football Club) to create England’s first heart and lung screening centre.

The LumiraDx NT-proBNP test is the only NT-proBNP test currently available that can be used with a simple fingerstick.

Covering multiple clinical areas, the LumiraDx platform is also ideally positioned for lung health screening and other cardiometabolic disease screening, offering HbA1c, CRP, D-Dimer, Influenza A/B, RSV and SARS-CoV-2 antigen tests; all on one platform.

Shares traded up more than 150% in the premarket after the press release.

The $0.24 area was a resistance level after hours and has now become a potential support area.

Above it, upside targets are $0.30, $0.40, $0.50 and $0.60. Also, $0.80, $0.90 and $1 come into play.

Below $0.24 there is potential support at $0.23, $0.21, $0.20, $0.15, $0.12 and gap filling at $0.0892.

ACON – Up over 9% after signing letter of intent with ATEC to advance commercialization of Nociscan

Clarion (ACON), a health technology company that uses magnetic resonance spectroscopy (MRS) in the United States, dedicated to revolutionizing the approach to spine surgery.

This morning, the company announced that it has signed a letter of intent for a strategic partnership (LOI) with ATEC to advance the commercialization of Nociscan.

The partnership aims to incorporate Aclarion’s Nociscan surgical decision-making technology into ATEC’s AlphaInformatiX platform to better inform spine surgery.

Shares traded up more than 9% in premarket trading following the news.

$0.60 has acted as a support level in the premarket.

Above it, the upside targets are $0.70, $0.73 and then the market high at $0.85. Additionally, $1 and $1.20 come into play.

Below $0.60 there is a gap to fill at $0.5650 and then $0.50 comes into play.

HARP – Up over 13% before after announcing 35% response rate in Phase 1/2 small cell lung cancer clinical trial

Harpoon Therapeutics (HARP) is a clinical-stage immunotherapy company developing a new class of T cell activators that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases in the United States.

Over the weekend, the company announced that it achieved a confirmed response rate of 35% (11/31) across all tumor types and patient cohorts treated with the 1 mg starting dose, including three confirmed, complete responses in a phase 1/2 clinical trial of t-cell engaging hpn328 evaluating HPN328 in small cell lung cancer (SCLC) and other types of neuroendocrine tumors in a poster at the European Society of Medical Oncology (ESMO) 2023 Congress.

HARP is now on track to select Phase 2 dose(s) by the end of 2023.

HARP found buyers in the pre-market at $9 and this level is now becoming a potential resistance zone.

Above it, upside targets are $10, $11 and then the pre-market high of $12.90.

Below $9 there is potential support at $7.40 and then a gap to fill at $6.88.

Questions or concerns about our products? Email [email protected] © Copyright 2022, RagingBull

REFUTATION To more fully understand any Ragingbull.com, LLC (“RagingBull”) subscription, website, application or other service (“Services”), please review our full disclaimer located at https://ragingbull.com /disclaimer

FOR EDUCATIONAL AND INFORMATIONAL PURPOSES ONLY; NOT INVESTMENT ADVICE. Any service offered by RagingBull is for educational and informational purposes only and should NOT be construed as an offer or solicitation of securities or relied upon as personalized investment advice. RagingBull strongly recommends that you consult a licensed or registered professional before making any investment decision.

THE RESULTS PRESENTED ARE NOT TYPICAL OR VERIFIED. The RagingBull Services may contain information regarding the historical trading performance of RagingBull’s owners or employees and/or testimonials from non-employees describing profitability that is believed to be true based on the statements of individuals who voluntarily provide the recommendations. However, Subscribers’ trading results are NOT tracked or verified and past results are not necessarily indicative of future results, and the results presented in this message are NOT TYPICAL. Actual results will vary significantly depending on factors such as experience, skill, risk mitigation practices, market dynamics and amount of capital employed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more of your initial investment.

RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment adviser (IA) or IA representative with the US Securities and Exchange Commission, any state regulatory securities authority or any self-regulatory organization. Employees, owners and other service providers of https:// ragingbull. com or RagingBull.com LLC receive a commission in whole or in part based on their sales of Services to Subscribers.

RagingBull.com, LLC is entitled to recover attorneys’ fees, costs and disbursements. In the event a lawsuit or action is brought as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any claim or action is necessary to enforce or interpret these Terms of Use, RagingBull. com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled.

WE CAN HAVE A DISCUSSION ON SECURITIES. RagingBull has not received payment directly or indirectly from the issuer of any security mentioned in the Services, other than possibly from the advertisers in this email. However, Ragingbull.com, LLC, its owners and its employees may buy, sell or hold long or short positions in securities of the companies mentioned in this announcement.

Leave a Comment

Your email address will not be published. Required fields are marked *